MT Meipept
Finnrick has tested 17 samples from MT Meipept across 3 products.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| GHK-Cu | 4 | 4 Feb 2026 | 24 Jun 2026 | |||||
| Retatrutide | 7 | 22 Jan 2026 | 24 Jun 2026 | |||||
| Tirzepatide | 6 | 22 Jan 2026 | 1 Jul 2026 | |||||
The MT Meipept samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Most recent MT Meipept tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 1 Jul 2026 | Tirzepatide | View | 20mg | 23.1mg | +15.5% | 99.90% | Jan 4,2026 | No label / Silver crimp / Purple cap | Lab E | Public | |
| 24 Jun 2026 | Retatrutide | View | 15mg | 13.7mg | -8.7% | 99.90% | April 2, 2026 | No label / Silver crimp / Clear Pink cap | Lab E | Public | |
| 24 Jun 2026 | GHK-Cu | View | 50mg | 44.4mg | -11.2% | 99.90% | March 3.2026 | No label / Silver crimp / Blue cap | Lab E | Public | |
| 2 Jun 2026 | Retatrutide | View | 10mg | 9.43mg | -5.7% | 99.90% | Jan 31 2026 Blue Cap | No Label / Silver Crimp / Clear Blue Cap | Lab E | Public | |
| 27 May 2026 | GHK-Cu | View | 50mg | 37.6mg | -24.8% | 99.90% | Dark Blue Cap CU50 | No Label / Silver Crimp / Blue Cap | Lab E | Public | |
| 27 May 2026 | Tirzepatide | View | 10mg | 18mg | +80.0% | 99.80% | March 3 2026 green cap | No Label / Silver Crimp / Clear Green Cap | Lab E | Public | |
| 20 Feb 2026 | Tirzepatide | View | 15mg | 26.3mg | +75.3% | 99.90% | December 19 2025 | (no data) | Lab E | Public | |
About MT Meipept Test Results From Finnrick
MT Meipept is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 3 products and 17 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud). Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
MT Meipept Testing Activity & Score Summary
In the past 30 days, Finnrick has published no new test results for MT Meipept, and 4 in the past three months. The overall dataset includes 17 tested samples with an average score of 8.1/10 across all products.
Across 17 identity-tested samples, 100% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.9%. Approximately 100% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- GHK-Cu (4 tests, 100% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 6.9 to 10.0 (average 8.3/10), suggesting significant batch-to-batch differences.
- Tirzepatide (6 tests, 100% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 6.0 to 9.6 (average 7.3/10), suggesting significant batch-to-batch differences.
- Retatrutide (7 tests, 100% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 6.2 to 9.8 (average 8.7/10), suggesting significant batch-to-batch differences.